Safety
Tesamorelin results: what the label and trials show
What tesamorelin (Egrifta) did in two label trials, how long it took, what happened after stopping, and what is not shown for fat loss. Read 18 Nov 2026.
By Julian Caraulani · Updated November 18, 2026
In the two trials on the FDA label, tesamorelin lowered deep belly fat in adults with HIV lipodystrophy over 26 weeks, and the fat came back in people switched to a dummy shot (DailyMed, Egrifta WR, read 18 Nov 2026). The label does not show weight loss or fat loss in other adults.
Price checked Nov 20 · Medication included · No email needed
Tesamorelin is FDA-approved as Egrifta for that one use. Compounded versions are not FDA-approved, and tesamorelin is not one of the six peptides under the interim HHS policy of 28 Oct 2026 (Federal Register 2026-22192). See the peptide legal status tracker for dated changes.
What the trials tested
The label describes "Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in HIV-infected patients with lipodystrophy." Lipodystrophy is a change in where the body stores fat. Neither the patients nor the doctors knew who got the drug.
The first study "randomized 412 HIV-infected patients with lipodystrophy and excess abdominal fat." The second "randomized 404 HIV-infected patients with lipodystrophy and excess abdominal fat." The main measure was "the percent change from baseline to Week 26 in visceral adipose tissue (VAT), as assessed by computed tomography." Visceral fat is the deep fat around the organs, measured with a CT scan.
How long tesamorelin takes to work
The label reports the main result at 26 weeks, about six months. It does not give a week when most people first notice a change. Scans, not the mirror, measured the result.
In study 1, deep belly fat fell by 27 cm² with tesamorelin and rose by 4 cm² with placebo. In study 2, it fell by 21 cm² with tesamorelin and did not change with placebo (label Table 2, read 18 Nov 2026). The label also says to "consider discontinuing EGRIFTA WR in patients who do not show a clear efficacy response," so your prescriber checks whether it is working.
Price checked Nov 20 · Medication included · No email needed
What happens after you stop
The label's 52-week extension followed people past week 26. Those who stayed on tesamorelin kept about the same deep belly fat. Those switched to placebo gained deep belly fat back: 25 cm² in study 1 and 24 cm² in study 2.
So the effect depended on staying on the drug in these trials. Ask your prescriber about the plan before you start.
Tesamorelin for belly fat and fat loss
The approved use is "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." The label adds that it "is not indicated for weight loss management as it has a weight neutral effect."
We found no trial on the label for belly fat or fat loss in adults without HIV. A prescriber may use a drug off-label, but results from the HIV trials do not prove the same effect in other people. Our peptides for weight loss guide covers what is approved for that goal.
Side effects seen in the trials
In the first 26 weeks, injection site reactions were reported by 17% of people on tesamorelin and 6% on placebo. Muscle pain was 6% versus 2%, and swelling in the arms or legs was 6% versus 2%. Joint pain was 13% versus 11%. Hypersensitivity reactions, such as rash or hives, were reported by 4% of people on tesamorelin.
The label also warns about tumor growth, higher blood sugar and fluid retention. Read the full label with your prescriber.
What it costs and where to get it
Licensed programs that compound tesamorelin start at $149.50 a month at Live Vital (2-month plan). Every listed program is on the tesamorelin price page. Compare programs in our best peptide programs ranking.
A compounded product is made by a state-licensed pharmacy for one patient and is not the approved Egrifta (FDA compounding page). We compare licensed prescription programs only, and we publish no doses. For more on the drug, read our tesamorelin overview.
FAQ
What are tesamorelin results?
In the two label trials, deep belly fat measured by CT scan fell over 26 weeks in adults with HIV lipodystrophy, while it rose or stayed level on placebo. The label shows no weight loss benefit and says the drug is weight neutral.
How long does tesamorelin take to work?
The label reports its main result at 26 weeks, about six months, using CT scans. It does not say when people first notice a change. If there is no clear response, the label says to consider stopping, so your prescriber reviews progress.
Does tesamorelin work for belly fat?
It did in the label trials, but only in adults with HIV and lipodystrophy, and for deep fat measured by scan. We found no label trial in adults without HIV, so the same result cannot be assumed for them.
Does tesamorelin work for fat loss?
The label states it is not indicated for weight loss management. Its trials measured deep belly fat in one group, not total body weight. Fat loss in other adults is not shown on the label.
What happens when you stop tesamorelin?
In the 52-week extension, people switched to placebo regained deep belly fat, 25 cm² and 24 cm² in the two studies. Those who stayed on tesamorelin held steady. The label does not give a general rule for everyone.
Is tesamorelin FDA-approved?
Yes, as Egrifta, for reducing excess belly fat in HIV-infected adults with lipodystrophy. Compounded tesamorelin from a pharmacy is not FDA-approved and is not the same product.
Bottom line
Tesamorelin has real trial evidence for one narrow group, and that evidence does not extend to general fat loss. To price a licensed program, see the cost page or the best peptide programs.
Check this page with an AI assistant:ChatGPTPerplexityClaude
Not affiliated with OpenAI, Perplexity or Anthropic.